AbCellera Biologics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 32.01, 34.36, 40.44, 78.57, 150.8 ], "ebit_estimate": [ -245.61, -271.92, -309.1, -307.69, -282.37 ], "ebitda_estimate": [ -231.4, -255.3, -220.5, -218.9, null ], "net_income_estimate": [ -197.79, -242.75, -284.54, -280.44, -256.04 ], "per_share_eps_estimate": [ -0.66, -0.73, -0.84, -0.79, -0.69 ], "eps_nri_estimate": [ -0.65, -0.71, -0.84, -0.79, -0.69 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -222.97, -256.59, -281.08, -288.74, -250.56 ], "operating_cash_flow_per_share_estimate": [ -0.38, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null ], "gross_margin_estimate": [ 100, 100, 100, 100, null ], "operating_cash_flow_estimate": [ -115.17, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -18.54, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -18.75, "future_eps_nri_estimate_growth": -18.54, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -12.32, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -24.59, "future_pretax_income_estimate_growth": -13.79, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 7.85, 7.68, 8.28, 7.78, 8.17, 8.37, 8.8 ], "ebit_estimate": [ -60.75, -61.73, -64.12, -65.42, -66.69, -68.03, -69.43 ], "ebitda_estimate": [ -62.4, -58.3, -60.1, -63.7, -65.4, -62.1, -64.1 ], "net_income_estimate": [ -50.38, -53.33, -55.95, -58.92, -60.38, -61.91, -63.53 ], "per_share_eps_estimate": [ -0.17, -0.16, -0.16, -0.19, -0.2, -0.2, -0.21 ], "eps_nri_estimate": [ -0.17, -0.16, -0.16, -0.19, -0.2, -0.2, -0.21 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -54.26, -57.47, -59.51, -58.92, -60.38, -61.91, -63.53 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 100, 100, 100, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -18.54, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -18.75, "future_eps_nri_estimate_growth": -18.54, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -12.32, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -24.59, "future_pretax_income_estimate_growth": -13.79, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }